Lv1
40 积分 2024-12-31 加入
Efficacy and safety of dotinurad versus febuxostat for the treatment of gout: a randomised, multicentre, double‐blind, phase 3 trial in China
1年前
已完结
Comparative efficacy and safety of uricosuric agents in the treatment of gout or hyperuricemia: a systematic review and network meta-analysis
1年前
已完结
Efficacy and safety of dotinurad versus febuxostat for the treatment of gout: a randomised, multicentre, double‐blind, phase 3 trial in China
1年前
已完结
Evaluation of the efficacy and safety of a novel xanthine oxidase inhibitor, tigulixostat, in gout patients with hyperuricemia: Design of the EURELIA 1 and EURELIA 2 studies
1年前
已完结
Febuxostat leads to better cardiovascular outcomes compared to allopurinol in patients with advanced chronic kidney disease: A Population-based Cohort Study
1年前
已完结
Febuxostat leads to better cardiovascular outcomes compared to allopurinol in patients with advanced chronic kidney disease: A Population-based Cohort Study
1年前
已完结
Cardiovascular outcomes of febuxostat and allopurinol: A long-term Taiwanese nationwide cohort study
1年前
已关闭
Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review
1年前
已完结
Low‐dose febuxostat exhibits a superior renal‐protective effect and non‐inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double‐centre, randomized, controlled study
1年前
已完结
Comparison between the Effects of Allopurinol and Febuxostat on the Survival of Patients on Maintenance Hemodialysis
1年前
已关闭
皖公网安备34019202002308
